Assessment of pharmacodynamic efficacy biomarkers from A phase 1, first-in-human study of arlocabtagene autoleucel (arlo-cel) in relapsed and refractory multiple myeloma (RRMM)
Safiyyah Ziyad(Bristol-Myers Squibb (United States)), Jesús G. Berdeja(Tennessee Oncology), Myo Htut(City Of Hope National Medical Center), Allison Kaeding(Bristol-Myers Squibb (United States)), Ziyan Guo(Bristol-Myers Squibb (Sweden)), Larry D. Anderson(Dana-Farber Cancer Institute), Ethan Thompson(Bristol-Myers Squibb (United States)), Tara Gregory(Colorado Blood Cancer Institute), Omar Nadeem(Harvard University), Naomey Sarkis(Bristol-Myers Squibb (United States)), Michael R. Burgess(Bristol-Myers Squibb (United States)), Wei-Ming Kao(Bristol-Myers Squibb (United States)), Hongxiang Hu(Bristol-Myers Squibb (United States)), Shari M. Kaiser(Bristol-Myers Squibb (United States)), Luciano da Fontoura Costa(Universidade de São Paulo), Susan Bal(University of Alabama at Birmingham Hospital), Kristina M. Jordahl(Bristol-Myers Squibb (United States))
Cited by 0
Related Papers
Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma
|New England Journal of Medicine|2019|1.7k
Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma
|New England Journal of Medicine|2023|695
Subtype and pathway specific responses to anticancer compounds in breast cancer
|Proceedings of the National Academy of Sciences|2011|505
International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders
|The Lancet Oncology|2019|493